Toughbuilt Industries Announces Receipt Of Nasdaq Delinquency Notice

Toughbuilt Industries, Inc. (NASDAQ:TBLT), announced that on April 19, 2024, it received a staff determination notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") informing the

Toughbuilt Industries, Inc. (NASDAQ:TBLT), announced that on April 19, 2024, it received a staff determination notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that since the Company has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Annual Report”), the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”).

 

ToughBuilt has 60 calendar days from April 19, 2024, to submit a plan to Nasdaq outlining the Company’s anticipated steps to regain compliance with the Listing Rule. The Company plans to submit the plan explaining the strategy to make the required SEC filings, and to regain compliance with the Listing Rule.

The Company is committed to fulfilling its reporting obligations and anticipates filing the Annual Report at the earliest opportunity, with plans to keep Nasdaq fully informed throughout this process.

Total
0
Shares
Related Posts
Read More

Regeneron Pharmaceuticals Announced Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH 2022

- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new and updated data from a Phase 1 and pivotal Phase 2 trial (ELM-1 and ELM-2) evaluating investigational odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

REGN